DCIS is a pre-invasive breast cancer condition with uncertain progression, often leading to aggressive treatment despite its "stage 0" classification. The lack of definitive guidance for DCIS ...
SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer versus guideline-recommended treatment, the randomized COMET ...
A diagnosis of ductal carcinoma in situ (DCIS) might seem reassuring compared to invasive breast cancer, but recent research paints a more nuanced picture about this condition that affects roughly ...
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001 A population-based cohort diagnosed with pure DCIS treated with ...
Adjuvant tamoxifen may reduce recurrence risk for patients with ‘good-risk’ DCIS who forgo radiation
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...
Hosted on MSN
Clinical trial: Adjuvant tamoxifen may reduce recurrence risk for patients with 'good-risk' DCIS who forgo radiation
For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results